https://www.selleckchem.com/products/Staurosporine.html coli and S. aureus with the antibacterial rates up to 99.3% and 99.8%, respectively. Mechanism investigation indicated that the slowly released Cu2+ ions could destroy the microenvironment of bacteria cells and destroy the integrity and permeability of the cell membrane, leading to enzyme inactivation. Therefore, the as-prepared flexible fibrous membrane will advance progress toward developing a broad spectrum antibacterial textile for healthcare protection related applications. The COVID-19 pandemic has raised unprecedented challenges in the management of patients with cancer and has increased the demands for digital health tools that, for example, could facilitate remote monitoring of patients. Based on this, the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) has recently developed a digital health tool dedicated to patients with hematologic malignancies the GIMEMA-ALLIANCE platform. The main objectives of this web-based platform are to generate relevant data to better understand quality of life, symptoms, and medication adherence during the COVID-19 pandemic and postpandemic era; to develop a prospective real-life registry on outcomes of patients with hematologic cancer, with or without a diagnosis of COVID-19; and to facilitate patient-centered care in routine practice. The platform consists of physician- and patient-secure portals and enables electronic patient-reported outcome (ePRO) assessments with real-time graphical presentation to physicians of individualCOVID-19 diagnosis and COVID-19 vaccination, will allow the development of a large database to also identify subgroups of patients at risk of poor outcomes. Data generated via this platform will help to answer clinically relevant questions for patients with hematologic malignancies during the COVID-19 pandemic and postpandemic era. The use of the GIMEMA-ALLIANCE platform in routine practice may also contribute to enhancing patient-centere